Triple-Hormone Drug Clears Two Phase 3 Trials, With Striking Weight Loss but Uncertain Cardiovascular Benefit
Retatrutide produced average weight loss of more than 20% in two high-risk populations—people with diabetes and those with established cardiovascular disease—giving Lilly the core clinical data needed for planned global submissions; however, an insufficient number of events means whether it can truly reduce cardiovascular risk remains inconclusive.